Cedric O'Gorman - 23 May 2023 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Reporting relationship: Chief Medical Officer
Issuer ticker: RLMD
Reported as of: 23 May 2023
Net transaction value: +$31,800
SEC form: 4
Accepted by SEC: 24 May 2023, 09:00:22 UTC
Prior SEC filing: 13 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Cedric O'Gorman

Key filing fact

Cedric O'Gorman filed Form 4 for RELMADA THERAPEUTICS, INC. (RLMD) on 24 May 2023.

Key facts

This page summarizes Cedric O'Gorman's Form 4 filing for RELMADA THERAPEUTICS, INC. (RLMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 May 2023, 09:00.

Change

Previous filing in this sequence was filed on 13 Jan 2023.
Current net transaction value: +$31,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RLMD transaction

Common Stock

Purchase

Transaction value: $31,800
Shares: +10,000
Change %: +8264%
Price: $3.18
Shares after: 10,121
Date: 23 May 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

Footnote F2

Purchase prices range from $3.135 to $3.2096 per share, inclusive.